首页 正文

Drugs of today (Barcelona, Spain : 1998). 2019 Aug;55(8):485-494. doi: 10.1358/dot.2019.55.8.3005176 Q40.02025

Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma

塞普利单抗治疗晚期皮肤鳞状细胞癌 翻译改进

T Hernández-Guerrero  1, B Doger  1, V Moreno  2

作者单位 +展开

作者单位

  • 1 Fundación Jiménez Díaz University Hospital, Madrid, Spain.
  • 2 Fundación Jiménez Díaz University Hospital, Madrid, Spain. victor.moreno@startmadrid.com.
  • DOI: 10.1358/dot.2019.55.8.3005176 PMID: 31461085

    摘要 Ai翻译

    Cutaneous squamous cell carcinoma (cSCC) is the second most frequent type of malignancy in Caucasians worldwide. Several factors have been correlated with aggressiveness and likelihood of recurrence and distant metastases, which are challenging to control. Metastatic disease has a dismal prognosis, and standard chemotherapy has failed to significantly improve outcomes. Recently, it has been recognized that cSCCs are highly mutated tumors with a denoting po... ...点击完成人机验证后继续浏览
    Copyright © Drugs of today (Barcelona, Spain : 1998). 中文内容为AI机器翻译,仅供参考!

    相关内容

    期刊名:Drugs of today

    缩写:DRUG TODAY

    ISSN:1699-3993

    e-ISSN:1699-4019

    IF/分区:0.0/Q4

    文章目录 更多期刊信息

    全文链接
    引文链接
    复制
    已复制!
    推荐内容
    Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma